The phrase "a collaborative programme between" is correct and usable in written English.
It can be used when describing a joint effort or initiative involving two or more parties working together towards a common goal.
Example: "The university has launched a collaborative programme between its engineering and business departments to foster innovation."
Alternatives: "a joint initiative involving" or "a partnership project between".
This paper presents the results of a collaborative programme of action between the European Federation of Inland Ports (EFIP) and the EC PORTOPIA research project to assist EU inland ports to enhance further their environmental performance.
This initiative was developed three years ago; it is a collaborative programme that involves meat scientists, electrical engineers and commercial meat processors.
Examples include: * The London Energy Project, a collaborative programme expected to save around £87m on energy bills over the next few years.
However, the present study is part of a more comprehensive collaborative programme between primary care and mental health services and we chose to employ only an active comparator in the protocol to match the real-world clinical setting as closely as possible.
Examples are the following: Collaborative Programme between CNRS, France and the State Committee of Science of the Republic of Armenia.
The increasing interest of the pharmaceutical industry in using pluripotent human stem cells in safety pharmacology and toxicology is also illustrated by collaborative programmes between the industry and research institutions on the development of hPSC-based in vitro test systems, such as the consortium Stem Cells for Safer Medicine (SC4SM; Jha 2007).
CHIP was a collaborative research programme between two UK-based organizations Save the Children and the Chronic Poverty Research Centre and partners in China, India, Kyrgyzstan and Mongolia.
ZD1694 ('Tomudex'), a novel, direct and specific thymidylate synthase (TS) inhibitor, was developed in a collaborative research programme between Zeneca Pharmaceuticals and the Institute of Cancer Research (UK) and entered clinical trials in 1991; phase II studies began in 1992, using 3.0 mg m-2 every 3 weeks as a short 15 min infusion.
